Search results for "Drug carrier"

showing 10 items of 329 documents

Pentafluorophenyl Ester-based Polymersomes as Nanosized Drug-Delivery Vehicles

2015

In this work, activated ester chemistry is employed to synthesize biocompatible and readily functionalizable polymersomes. Via aminolysis of pentafluorophenyl methacrylate-based precursor polymers, an N-(2-hydroxypropyl) methacrylamide (HPMA)-analog hydrophilic block is obtained. The precursor polymers can be versatile functionalized by simple addition of suitable primary amines during aminolysis as demonstrated using a fluorescent dye. Vesicle formation is proven by cryoTEM and light scattering. High encapsulation efficiencies for hydrophilic cargo like siRNA are achieved using dual centrifugation and safe encapsulation is demonstrated by gel electrophoresis. In vitro studies reveal low cy…

PolymersomesMaterials sciencePolymers and Plastics02 engineering and technology010402 general chemistryMethacrylate01 natural scienceschemistry.chemical_compoundAminolysisHPMAPolymer chemistryMaterials ChemistryMethacrylamideReversible addition−fragmentation chain-transfer polymerizationRAFT polymerizationVesicleOrganic Chemistry021001 nanoscience & nanotechnologyCombinatorial chemistry0104 chemical scienceschemistrydrug deliveryPolymersomeDrug deliveryactivated esters0210 nano-technologyDrug carrierMacromolecular Rapid Communications
researchProduct

Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration

2022

In this work, the production of inhalable polymeric microparticles with modulable porosity is described. The starting polymeric material was the PHEA-g-RhB-g-PLA graft copolymer, which was suitably processed by spray drying (SD). Thanks to the addition of AB (weight percentage equal to 10 and 20 % with respect to the polymer) in the liquid feed, three biocompatible matrices were obtained with an increasing porosity in terms of pore volume (from 0.015 to 0.024 cc/g) and pore average diameter (from 1.942 to 3.060 nm), a decreasing tapped density values (from 0.75 to 0.50), and favorable aerosolization characteristics. These differences were high-lighted also by a significant increase in the r…

Porous microparticlesDrug CarriersPolymersSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAdministration InhalationPharmaceutical SciencePulmonary administrationRapamycinPowdersParticle SizePorosityαβ-Poly(N-2-hydroxyethyl)-Dl-ASPARTAMIDE (PHEA)
researchProduct

Caspase 3 Targeted Cargo Delivery in Apoptotic Cells Using Capped Mesoporous Silica Nanoparticles

2015

[EN] Excessive apoptotic cell death is at the origin of several pathologies, such as degenerative disorders, stroke or ischemia-reperfusion damage. In this context, strategies to improve inhibition of apoptosis and other types of cell death are of interest and may represent a pharmacological opportunity for the treatment of cell-death-related disorders. In this scenario new peptide-containing delivery systems (solids S1-P1and S1-P2) are described based on meso-porous silica nanoparticles (MSNs) loaded with a dye and capped with the KKGDEVDKKARDEVDK (P1) peptide that contains two repeats of the DEVD target sequence that are selectively hydrolyzed by caspase3 (C3). This enzyme plays a central…

Programmed cell deathgated mesoporous materialsCaspase 3Context (language use)ApoptosisCatalysisGated mesoporous materialsHeLaQUIMICA ORGANICAQUIMICA ANALITICAmedicineBIOQUIMICA Y BIOLOGIA MOLECULARControlled releaseHumansCisplatinDrug CarriersbiologyChemistryCaspase 3Organic ChemistryQUIMICA INORGANICAGeneral ChemistryMesoporous silicabiology.organism_classificationSilicon DioxideMolecular biologyCell biologycaspase3ApoptosisCytoplasmpeptidesNanoparticlesnanoparticlesCisplatinPeptidescontrolled releasePorositymedicine.drugHeLa Cells
researchProduct

Hydrophilicity Regulates the Stealth Properties of Polyphosphoester‐Coated Nanocarriers

2018

Increasing the plasma half-life is an important goal in the development of drug carriers, and can be effectively achieved through the attachment of polymers, in particular poly(ethylene glycol) (PEG). While the increased plasma half-life has been suggested to be a result of decreased overall protein adsorption on the hydrophilic surface in combination with the adsorption of specific proteins, the molecular reasons for the success of PEG and other hydrophilic polymers are still widely unknown. We prepared polyphosphoester-coated nanocarriers with defined hydrophilicity to control the stealth properties of the polymer shell. We found that the log P value of the copolymer controls the composit…

Protein Corona02 engineering and technology010402 general chemistry01 natural sciencesCatalysisPolyethylene GlycolsMicechemistry.chemical_compoundDrug Delivery SystemsPEG ratioAnimalsHumanschemistry.chemical_classificationDrug CarriersMolecular StructureChemistryGeneral ChemistryPolymer021001 nanoscience & nanotechnology0104 chemical sciencesRAW 264.7 CellsBiophysicsPEGylationNanoparticlesNanocarriers0210 nano-technologyDrug carrierHydrophobic and Hydrophilic InteractionsEthylene glycolHeLa CellsProtein adsorptionAngewandte Chemie International Edition
researchProduct

Polyanion–tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2016

Aim: Efficacy of antibiotics in cystic fibrosis (CF) is compromised by the poor penetration through mucus barrier. This work proposes a new ‘nano-into-micro’ approach, used to obtain a combinatorial effect: achieve a sustained delivery of tobramycin and overcome mucus barrier. Methods: Mannitol microparticles (MPs) were loaded with a tobramycin polymeric nanocomplex and characterized in presence of CF artificial mucus. Results & discussion: MPs are able to alter the rheological properties of CF artificial mucus, enhancing drug penetration into it and allowing a prolonged drug release. MPs resulted to be effective in Pseudomonas aeruginosa infections if compared with free tobramycin. Co…

Pseudomonas aeruginosa infectionCystic FibrosisPolymersmedicine.drug_classAntibioticsBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyDevelopmentBiologySettore BIO/19 - Microbiologia Generalenano into micro strategyCystic fibrosisCell LineNanocompositesMicrobiology03 medical and health sciences0302 clinical medicineAntibiotic resistancePseudomonas aeruginosa InfectionsmedicineTobramycinHumansMannitolPseudomonas InfectionsGeneral Materials ScienceDrug CarriersEpithelial CellsPenetration (firestop)021001 nanoscience & nanotechnologymedicine.diseasePolyelectrolytesMucusAnti-Bacterial AgentsDrug LiberationMucusmicroparticle030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico Applicativocystic fibrosis artificial mucuPseudomonas aeruginosaTobramycinMannitol0210 nano-technologyαβ-poly(N-2-hydroxyethyl)-DL-aspartamidespray dryermedicine.drugNanomedicine
researchProduct

Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2019

Abstract Sustained pulmonary delivery of tobramycin from microparticles composed of drug/polymer nanocomplexes offers several advantages against traditional delivery methods. Namely, in patients with cystic fibrosis, microparticle delivery can protect the tobramycin being delivered from strong mucoadhesive interactions, thus avoiding effects on its diffusion toward the infection site. Polymeric ion-pair complexes were obtained starting from two synthetic polyanions, through impregnation of their solid dissociated forms with tobramycin in aqueous solution. The structure of these polymeric systems was characterized, and their activities were examined against various biofilm-forming Pseudomona…

Pseudomonas aeruginosa infectionpseudomonas aeruginosa infectionsBiocompatibilityCystic FibrosisαPharmaceutical Science02 engineering and technologymedicine.disease_cause030226 pharmacology & pharmacyCystic fibrosisCell Line03 medical and health sciences0302 clinical medicineIon-pair complexmedicineTobramycinHumansPseudomonas InfectionsMicroparticleαβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)chemistry.chemical_classificationDrug CarriersAqueous solutionPseudomonas aeruginosaBiofilms; Cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; Pseudomonas aeruginosa infections; Tobramycin; α; β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)BiofilmBiofilmPolymerBiofilms; cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; pseudomonas aeruginosa infections; Tobramycin; αβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)021001 nanoscience & nanotechnologymedicine.diseaseAnti-Bacterial AgentsMucuschemistryBiofilmsPseudomonas aeruginosaBiophysicsTobramycinNanoparticlescystic fibrosis artificial mucus (CF-AM)0210 nano-technologyPeptidesmedicine.drug
researchProduct

Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.

2003

The influence of the secretion process on the absorption of ciprofloxacin, grepafloxacin and sparfloxacin has been evaluated by means of inhibition studies. Two well known P-glycoprotein inhibitors (cyclosporine, verapamil), a mixed inhibitor of P-glycoprotein and the organic cation transporter OCT1 (quinidine) and a well established MRP substrate (p-aminohipuric acid) have been selected in order to distinguish the possible carriers implicated. An in situ rat gut perfusion model and CACO-2 permeability studies are used. Both methods suggest the involvement of several types of efflux transporters for every fluoroquinolone. The relevance of the secretory pathway depends on the intrinsic perme…

QuinidineMalePharmaceutical ScienceBiological AvailabilityPharmacologyIn Vitro TechniquesModels BiologicalIntestinal absorptionPiperazinesAnti-Infective AgentsCiprofloxacinmedicineAnimalsHumansRats WistarChromatography High Pressure LiquidAntibacterial agentDrug CarriersOrganic cation transport proteinsbiologyGeneral MedicineGrepafloxacinIn vitroRatsSparfloxacinIntestinal Absorptionbiology.proteinVerapamilCaco-2 CellsBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

In vivo delivery of human alpha 1-antitrypsin gene to mouse hepatocytes by liposomes.

1993

The pTG7101 plasmid containing the full length human alpha 1-Antitrypsin was encapsulated in large (142 +/- 15 nm of diameter) and small (54 +/- 11 nm of diameter) liposomes and administered i.v. to mice (80 ng/mouse). Control animals were treated with empty (small and large) liposomes plus free DNA and with the liposome solvent buffer. The immunohistochemical results on liver cryosections and cytophotometric analysis of hepatocyte chromophore absorbance, after peroxidase reaction, indicated that significant presence of immunoreactive human alpha 1-antitrypsin was present 7 days after mice treatment with encapsulated DNA in small liposomes but not when large liposomes were used. This effect…

RatónBiophysicsSynthetic membraneBiologyBiochemistrychemistry.chemical_compoundMicePlasmidIn vivomedicineAnimalsHumansMolecular BiologyLiposomeDrug CarriersGenetic transferCell BiologyDNAMolecular biologyImmunohistochemistrymedicine.anatomical_structureBiochemistrychemistryLiverHepatocytealpha 1-AntitrypsinLiposomesDNAPlasmidsBiochemical and biophysical research communications
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Influence of Riboflavin Targeting on Tumor Accumulation and Internalization of Peptostar Based Drug Delivery Systems.

2020

Riboflavin carrier protein (RCP) and riboflavin transporters (RFVTs) have been reported to be highly overexpressed in various cancer cells. Hence, targeting RCP and RFVTs using riboflavin may enhance tumor accumulation and internalization of drug delivery systems. To test this hypothesis, butyl-based 3-arm peptostar polymers were synthesized consisting of a lysine core (10 units per arm) and a sarcosine shell (100 units per arm). The end groups of the arms and the core were successfully modified with riboflavin and the Cy-5.5 fluorescent dye, respectively. While in phosphate buffered saline the functionalized peptostars showed a bimodal behavior and formed supramolecular structures over tim…

SarcosinePolymersmedia_common.quotation_subjectRiboflavinLysineBiomedical EngineeringPharmaceutical ScienceBioengineeringRiboflavinchemistry.chemical_compoundIn vivoRiboflavin-carrier proteinMaterials TestingHumansInternalizationmedia_commonPharmacologyDrug CarriersChemistryLysineOrganic ChemistryMembrane Transport ProteinsBiological TransportSarcosineCarbocyaninesCancer cellDrug deliveryPC-3 CellsBiophysicsBiotechnologyBioconjugate chemistry
researchProduct